Fusion Antibodies Plc

Company Overview

Fusion Antibodies is a highly specialised CRO (contract research organisation) operating in the[CM1] field of monoclonal antibody (mAb) production and engineering. The global CRO market is estimated to be worth over $30bn growing at a CAGR of c 12% pa to 2020. The Company is well established and differentiated by means of its expertise, technology and the quality of its partnerships. The existing customer base includes top five ‘big pharma’, and is globally spread. Fusion has a proven record of revenue growth (up by 220% from FY15-17) with a FY17 reported EBITDA margin of 8%. The Company is entering a period of expansion targeting geographic growth and investing in greater capacity to meet sustained demand for its services.
 

Date Reports Available Download
20 November 2020 Interims 3 pages
19 August 2020 FY 2020 3 pages
28 April 2020 Update post £3m placing 3 pages
05 December 2019 Interims - Meeting expectations: sustained growth in H1 3 pages
02 July 2019 FY 2019 Results - Strong 2H 10 pages
17 April 2019 Trading update 3 pages
25 February 2019 Trading update 3 pages
26 November 2018 2019 Interims 4 pages
16 August 2018 FY 2018 9 pages
05 March 2018 Trading Update 2 pages
23 January 2018 Initiation 32 pages